Skip to main content
. Author manuscript; available in PMC: 2022 Jan 14.
Published in final edited form as: J Card Fail. 2021 Jul 18;27(12):1447–1455. doi: 10.1016/j.cardfail.2021.07.003

Fig. 4.

Fig. 4.

Putative sodium-centric mechanisms of benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitors in people with type 2 diabetes (T2D) and cardiorenal disease. BP, blood pressure.